openPR Logo
Press release

Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017

10-25-2017 03:53 PM CET | Health & Medicine

Press release from: ReportsWorldwide

Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017

Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017

ReportsWorldwide has announced the addition of a new report title Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017 to its growing collection of premium market research reports.

Summary
Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders and Toxicology which include indications Short Bowel Syndrome, Chemotherapy Effects, Diabetes, Diarrhea, Gastrointestinal Mucositis, Obesity and Type 2 Diabetes.

The latest report Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41710

Scope
- The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
- The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/glucagon-like-peptide-2-receptor-glp2r-pipeline-review-h2-2017

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston,
MA 02110
US
Phone +1 (617) 398-1947

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017 here

News-ID: 786138 • Views:

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in Regenerative Medicine
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for GLP2

Short Bowel Syndrome Market Demand, Rising Trends and Technology Advancements 20 …
Patients with Short Bowel Syndrome at High Risk of Contracting Coronavirus Patients with gastrointestinal (GI) diseases may be at increased risk for more severe illness due to the ongoing COVID-19 outbreak. Potential risk factors in these patients include their chronic inflammatory disease, comorbidities, and the use of glucocorticoids. Healthcare, being an essential industry, has compelled manufacturers in the short bowel syndrome market to maintain robust supply chains for treatment options and
Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height
Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutic Pipeline Review, H2 2017
"The Report Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Glucagon Like Peptide 2 Receptor (GLP2R) Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in
Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review and Therapeutic Asses …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017” to its report offerings. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party source. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297806 Glucagon Like Peptide